Eli Lilly's Zepbound Achieves Remarkable 24% Weight Loss
Discover how Eli Lilly's weight-loss drug, Zepbound, delivers up to 24% weight loss, securing its competitive edge in the pharmaceutical market.
Topic
Eli Lilly
A collection of 4 issues
Novo Nordisk, Amgen, & Eli Lilly Navigate Weight-Loss Drug Challenges
Explore how Novo Nordisk, Amgen, and Eli Lilly tackle competition and supply constraints in the weight-loss drug market. Discover the latest industry insights.
Eli Lilly Shares Rise After Zepbound Sleep Apnea Approval
Eli Lilly sees stock surge as Zepbound receives regulatory approval for treating sleep apnea. Discover how this impacts the healthcare market.
Eli Lilly Stock Surges 32% YTD, Reaches $729 Billion Market Cap
Eli Lilly's stock performance shines with a 32% year-to-date increase, pushing its market capitalization to a remarkable $729 billion. Explore this growth trajectory.